Imipramine and children: a review and some speculations about the mechanism of drug action.
Although the FDA recommends imipramine hydrochloride (IMI) only for temporary relief of symptoms of enuresis nocturna (EN), the drug has been applied to a number of other pediatric situations, including the Hyperkinetic Syndrome (HS), childhood depression, somnambulism and pavor nocturnus, school phobia, petit mal epilepsy, allergies, autism, encorpresis and head-banging. We have reviewed the literature, with particular attention to the pharmacokinetics of IMI in children, and its putative mechanisms of action. The drug probably works through a number of different actions, and the futher delineation of these will be of considerable heuristic value. We review the toxic effects of IMI treatment and IMI poisoning in children, and the pediatric literature concerning other antidepressant drugs and lithium carbonate (Li).
D000293:Adolescent; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D003863:Depression / Q000188:drug therapy; D004298:Dopamine / Q000378:metabolism; D004775:Enuresis / Q000188:drug therapy; D004832:Epilepsy, Absence / Q000188:drug therapy; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D006321:Heart / Q000187:drug effects; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy; D007099:Imipramine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008774:Methylphenidate / Q000627:therapeutic use; D009638:Norepinephrine / Q000378:metabolism; D010698:Phobic Disorders / Q000188:drug therapy; D012574:Schools; D012893:Sleep Wake Disorders / Q000188:drug therapy; D013577:Syndrome
D008774:Methylphenidate; D013006:Growth Hormone; D007099:Imipramine; D004298:Dopamine; D009638:Norepinephrine